Qiufen Guo

324 Jingwu Road
Jinan, 250021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer.

Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer.

Journal: Gynecologic oncology

Published: September 12, 2025

Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial.

Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial.

Journal: International journal of radiation oncology, biology, physics

Published: April 05, 2025

Prognostic Value of Ferroptosis-Immunity-Related Signature Genes in Cervical Cancer Radiotherapy Resistance and Risk Modeling.

Prognostic Value of Ferroptosis-Immunity-Related Signature Genes in Cervical Cancer Radiotherapy Resistance and Risk Modeling.

Journal: Cancer management and research

Published: November 11, 2024

A Personalized Anisotropic Margin for Cervical Cancer Radiation Therapy Under the Guidance of Daily Iterative Cone-Beam Computed Tomography (iCBCT).

A Personalized Anisotropic Margin for Cervical Cancer Radiation Therapy Under the Guidance of Daily Iterative Cone-Beam Computed Tomography (iCBCT).

Journal: Cureus

Published: September 07, 2024

Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study.

Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study.

Journal: International immunopharmacology

Published: December 23, 2023

Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study.

Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study.

Journal: Medicine

Published: March 17, 2020

Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.

Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.

Journal: Gynecologic oncology

Published: September 25, 2014

Aberrant expression of hSef and Sprouty4 in endometrial adenocarcinoma.

Aberrant expression of hSef and Sprouty4 in endometrial adenocarcinoma.

Journal: Oncology letters

Published: August 28, 2014

Loss of expressions of Dusp6, Sprouty4, and Sef, negative regulators of FGF2/ERK1/2 signaling, in the endometrium of women with adenomyosis.

Loss of expressions of Dusp6, Sprouty4, and Sef, negative regulators of FGF2/ERK1/2 signaling, in the endometrium of women with adenomyosis.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: April 01, 2014

Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estradiol-induced cell growth in endometrial adenocarcinoma cell.

Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estradiol-induced cell growth in endometrial adenocarcinoma cell.

Journal: Molecular and cellular endocrinology

Published: August 26, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026